目的 探讨甘海胃康胶囊联合艾司奥美拉唑钠治疗反流性食管炎的临床效果。方法 选取2021年3月—2022年12月安阳市人民医院收治的122例反流性食管炎患者，按照随机数字表法分为对照组和治疗组，每组各61例。对照组静脉滴注注射用艾司奥美拉唑钠，每次将40 mg溶于100 mL的0.9%氯化钠注射液中，20～30 min/次，2次/d。治疗组在对照组治疗基础上口服甘海胃康胶囊，6粒/次，3次/d。两组疗程均为7 d。观察两组的临床疗效，比较两组治疗前后典型症状评分、汉密尔顿焦虑量表（HAMA）、17项汉密尔顿抑郁量表（HAMD-17）评分、胃食管反流病问卷（GerdQ）评分、内镜积分、食管24 h pH-阻抗监测参数变化。结果 治疗后，治疗组总有效率是96.72%，显著高于对照组的86.89%（P＜0.05）。治疗后，两组反酸、烧心、胸骨后痛评分均较治疗前显著下降（P＜0.05）；治疗后，治疗组典型症状评分显著低于对照组（P＜0.05）。治疗后，两组HAMA、HAMD-17、GerdQ评分和内镜积分均显著降低（P＜0.05）；治疗后，治疗组HAMA、HAMD-17、GerdQ评分和内镜积分均低于对照组（P＜0.05）。治疗后，两组反流总次数、最长反流时间及立位酸反流、液体反流和混合反流的次数均显著减少（P＜0.05）；且均以治疗组改善更显著（P＜0.05）。结论 甘海胃康胶囊联合艾司奥美拉唑钠治疗反流性食管炎具有较好的临床疗效，可明显改善临床症状与食管黏膜状态，同时可大幅提升精神心理状况及生活质量，值得临床推广应用。

Objective To explore the clinical effect of Ganhai Weikang Capsules combined with esomeprazole sodium in treatment of reflux esophagitis. Methods A total of 122 patients with reflux esophagitis treated in Anyang People’s Hospital from March 2021 to December 2022 were selected and divided into control group and treatment group according to random number table method, with 61 cases in each group. Patients in control group were iv administered with Esomeprazole Sodium for injection, 40 mg of this product was dissolved in 100 mL 0.9% sodium chloride injection, 20 — 30 min/time, twice daily. Patients in the treatment group were po administered with Ganhai Weikang Capsules on the basis of the control group, 6 grains/time, three times daily. The treatment course of both groups was 7 d. The clinical efficacy of two groups was observed. The changes of typical symptom scores, Hamilton Anxiety Scale (HAMA), 17 Hamilton Depression Scale (HAMD-17) scores, GerdQ scores, endoscopic scores, and esophageal 24-hour pH impedance monitoring parameters before and after treatment were compared between two groups. Results After treatment, the total effective rate of treatment group was 96.72%, significantly higher than that of control group (86.89%) (P < 0.05). After treatment, the scores of acid reflux, heartburn, and retrosternal pain in two groups were significantly decreased compared with those before treatment (P < 0.05). After treatment, the typical symptom score of treatment group was significantly lower than that of control group (P < 0.05). After treatment, HAMA, HAMD-17, GerdQ scores, and endoscopic scores were significantly decreased in both groups (P < 0.05). After treatment, HAMA, HAMD-17, GerdQ scores, and endoscopic scores in treatment group were lower than those in control group ( P < 0.05). After treatment, the total number of reflux, the longest reflux time and the number of orthostatic acid reflux, liquid reflux and mixed reflux were significantly reduced in both groups (P < 0.05). The improvement was more significant in treatment group (P < 0.05). Conclusion Ganhai Weikang Capsules combined with esomeprazole sodium has good clinical efficacy in treatment of reflux esophagitis, and can significantly improve clinical symptoms and esophageal mucosa status, and significantly improve mental and psychological status and life quality, which is worthy of clinical application.

R975

安阳市科技计划项目（2021C01SF045）